explore -WSS

explore

author：Wikipedia 2025-08-26 23:45:49 - browse：1894

Kevin Sayer, CEO of Dexcom Dexcom

For years, diabetes tech company Dexcom has been striving to get its continuous glucose monitors into the hands of type 2 diabetes patients. Last week at the American Diabetes Association’s conference, the company unveiled plans for software built entirely for these patients, including ones who don’t take insulin.

“We’ve been so focused on things that match the needs of somebody who manages diabetes every minute of every day, and insulin delivery,” Kevin Sayer, CEO of Dexcom, told STAT. “This new product is going to be designed to address the needs of somebody with diabetes who’s not doing that, who has type 2 diabetes and is on other drugs.”

Continuous glucose monitoring is already well-established among people with type 1 diabetes, who rely on constant insulin therapy. The technology, which helps patients noninvasively monitor their blood sugar levels and control their insulin pump in real time, has grown rapidly in use over the years, culminating in a $5 billion market.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： WATCH: Why do fingernails fall off when they're damaged?

WSS

Weight bias in eating disorder treatment complicated by new weight loss drugs

Why H5N1 bird flu is keeping the CDC's top flu scientist awake

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

STAT's guide to the next generation of CAR

Abbott's new stent may help patients with peripheral artery disease

Donald Trump's relentless attacks on special counsel Jack Smith

leisure time

explore

knowledge

Trump demands the U.S. pay no more for drugs than other countries … again

3 hurdles to bringing medical devices to the U.S. market

Moonlake's readout produced a cash windfall. Risks remain

Why drug prescriptions should include diagnoses

As demand for Covid shots wanes, Moderna seeks its next success

Gene therapy has helped boys walk. Can scientists keep it that way?

Hollywood unions extend contract negotiations for actors

Ask STAT: What do you want to know about ChatGPT in medicine?

Apple is now the first public company to be valued at $3 trillion

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

focus

ALS treatment from Biogen, Ionis fails in study

Fertility clinic egg and embryo storage is a disaster

Galapagos to make CAR

WuXi Biologics execs register to lobby as Congress comes for the company

Why drug prescriptions should include diagnoses

Why are elite athletes different? Take a look at their microbes

hotspot

leisure time

hotspot

focus